Drug intelligence / Profile preview

BCM-0250

Development stage: Preclinical
Lead developer: Biocidium Biopharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

BCM-0250 is an investigational antibiotic being developed by Biocidium Biopharmaceuticals for the treatment of multidrug-resistant (MDR) *Pseudomonas aeruginosa* infections. It is formulated for oral administration. The drug is part of Biocidium's pipeline focused on addressing antimicrobial resistance, particularly in Gram-negative bacteria such as *Pseudomonas aeruginosa*. Detailed information about its mechanism of action, chemical structure, or clinical trial phase beyond its indication and formulation has not been disclosed publicly[1].

Beyond the preview

Go deeper on BCM-0250.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCM-0250.

Explore the full profile